{"url_path":"/sec/ganx/8-k/2026-07-16/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-084086-index.html","accession_number":"0001104659-26-084086","cik":"0001819411","ticker":"GANX","issuer_name":"Gain Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-084086-index.html","primary_entity_key":"0001819411","primary_entity_name":"Gain Therapeutics, Inc."},"word_count":373,"has_tables":true,"body_markdown":"** **\n\n \n\n \n\n \n\n \n\n**Item 8.01. Other Events.**\n\n \n\nOn July 16, 2026, Gain Therapeutics, Inc. (the\n“Company”) issued a press release and shareholder letter in which it announced, among other things, that its current cash\nand cash equivalents are anticipated to fund the Company’s operations into the second quarter of 2027, based on current operating\nplans, including the completion of the Phase 1b open-label extension in October 2026 and initiation of a Phase 2 clinical study during\nthe third quarter of 2026.\n\n \n\n*Cautionary Note Regarding Forward-Looking Statements*\n\n* *\n\nThis Current Report on Form 8-K contains “forward-looking\nstatements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements\nare typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,”\n“will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s\ncurrent knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the\nexpectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that\nthose goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking\nstatements. Such forward-looking statements include, but are not limited to, statements regarding the Company’s cash runway. For\na further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking\nstatements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the\nyear ended December 31, 2025, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety\nby this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the\ndate of this release. The Company has no obligation, and expressly disclaims any obligation, to update, revise or correct any of the forward-looking\nstatements, whether because of new information, future events or otherwise.\n\n \n\n \n\n \n\n \n\n**Signature**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**GAIN THERAPEUTICS, INC.**\n\n \n \n\nDated: July 16, 2026\nBy:\n/s/ Gene Mack\n\n \n \nGene Mack\n\n \n \nChief Executive Officer"}